ZEPHYRx
PrivateLast Round
Grant
Aug 1, 2017
Total Funding Raised
$1.22M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
ZEPHYRx is a health technology company that provides an end-to-end, cloud-based platform for remote respiratory monitoring for clinical research and healthcare.
Sector
Healthcare & Life Sciences
Verticals
Telemedicine, Vertical SaaS, Health IoT, Clinical Trials, Patient Engagement
Business Model
B2B
Customer Profile
Hardware + Subscription, Subscription SaaS, Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ZEPHYRx Comparables
Compare ZEPHYRx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Monitored Therapeutics | 92% | |
| AioCare | 88% | |
| NuvoAir | 83% | |
ZEPHYRx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 1, 2017 |
ZEPHYRx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Heart, Lung, and Blood Institute | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Grew 19% QoQ, from 27 to 32 employees.
- Jan 12, 2026
Participates in START-UP NY program for employee tax exemptions.
ZEPHYRx Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |